H Lundbeck

Incorporated in 1915, Lundbeck is a pharmaceutical company headquartered in Valby, Copenhagen, Denmark, specializing in the field of neuroscience. The company's business endeavors are deeply rooted in the research, development, and marketing of treatments focused on psychiatric and neurological disorders. Lundbeck's product portfolio boasts a number of significant brands, which include Vyepti (eptinezumab), Rexulti (brexpiprazole), Brintellix/Trintellix (vortioxetine), Abilify Maintena (aripiprazole), and Northera (droxidopa). These products target debilitating conditions such as depression, schizophrenia, Parkinson's disease, and Alzheimer's disease. With a commercial presence in over 50 countries, Lundbeck has a strong international footprint, selling its products and services predominantly in the United States, China, Japan, Germany, and France. The company's success in the United States is particularly noteworthy, with this market being a significant contributor to its commercial success, mainly due to the country's market size and the performance of key products. (Powered by AI)